Increased plasminogen activator inhibition levels in malignancy.

Area of Science:

• Biochemistry
• Oncology
• Hematology

Background:

• Plasminogen activators (PAs) and their inhibitors play crucial roles in the fibrinolytic system.
• Alterations in PA levels and activity are implicated in various pathological conditions, including cancer.
• The relationship between fibrinolytic activity and tumor metastasis requires further elucidation.

Purpose of the Study:

• To investigate plasma levels of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), as well as PA-inhibition in cancer patients.
• To determine if these levels differ based on the presence or absence of tumor metastasis.
• To assess the role of fibrinolytic activity in tumor metastasis.

Main Methods:

• Blood samples were collected from 52 cancer patients with diverse tumor types.
• Patients were analyzed as a single group and then subdivided into those with (n=42) and without (n=10) metastasis.
• Plasma levels of t-PA antigen, u-PA, and PA-inhibition were measured and compared to age-matched healthy controls.

Main Results:

• Tissue-type plasminogen activator antigen (t-PA-antigen) and PA-inhibition were significantly elevated in cancer patients compared to controls (p < 0.001), irrespective of metastasis.
• Patients without metastasis exhibited significantly decreased t-PA activity (p < 0.001).
• In contrast, cancer patients with metastasis showed normal t-PA activity.

Conclusions:

• The study findings do not support the hypothesis that decreased plasma fibrinolytic activity is a prerequisite for tumor metastasis.
• Elevated t-PA antigen and PA-inhibition in cancer patients suggest a complex interplay within the fibrinolytic system.
• Further research is warranted to fully understand the implications of these findings in cancer progression and treatment.